| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 28 | 2019 | 2128 | 3.800 |
Why?
|
| Acute Kidney Injury | 23 | 2018 | 1890 | 2.970 |
Why?
|
| MicroRNAs | 14 | 2021 | 3674 | 2.080 |
Why?
|
| Kidney | 31 | 2021 | 6903 | 2.050 |
Why?
|
| Kidney Tubules, Proximal | 13 | 2019 | 429 | 1.860 |
Why?
|
| Cell Adhesion Molecules | 21 | 2015 | 1673 | 1.680 |
Why?
|
| Cisplatin | 9 | 2016 | 1663 | 1.330 |
Why?
|
| Fibrinogen | 5 | 2014 | 915 | 1.280 |
Why?
|
| Reperfusion Injury | 9 | 2013 | 1076 | 1.280 |
Why?
|
| Kidney Tubules | 7 | 2018 | 494 | 1.180 |
Why?
|
| Toxicology | 2 | 2019 | 125 | 0.990 |
Why?
|
| Fibrosis | 11 | 2021 | 1944 | 0.970 |
Why?
|
| Acetylglucosaminidase | 6 | 2014 | 79 | 0.840 |
Why?
|
| Membrane Glycoproteins | 11 | 2015 | 3862 | 0.810 |
Why?
|
| Heme Oxygenase-1 | 4 | 2019 | 385 | 0.770 |
Why?
|
| STAT3 Transcription Factor | 2 | 2014 | 905 | 0.740 |
Why?
|
| Toxicity Tests | 4 | 2015 | 137 | 0.730 |
Why?
|
| Receptors, Virus | 11 | 2015 | 658 | 0.730 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 1041 | 0.730 |
Why?
|
| Civil Defense | 1 | 2020 | 107 | 0.710 |
Why?
|
| Xenobiotics | 2 | 2016 | 79 | 0.680 |
Why?
|
| Chromium | 2 | 2016 | 133 | 0.650 |
Why?
|
| Technology, Pharmaceutical | 1 | 2017 | 91 | 0.640 |
Why?
|
| Phospholipase D | 1 | 2017 | 74 | 0.640 |
Why?
|
| RNA, Messenger | 10 | 2019 | 13292 | 0.630 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2016 | 87 | 0.590 |
Why?
|
| Biotechnology | 1 | 2017 | 279 | 0.570 |
Why?
|
| Systems Biology | 1 | 2019 | 492 | 0.540 |
Why?
|
| Drug Discovery | 2 | 2020 | 1067 | 0.540 |
Why?
|
| Acetaminophen | 4 | 2021 | 549 | 0.530 |
Why?
|
| Cysteine | 3 | 2003 | 871 | 0.520 |
Why?
|
| High-Throughput Screening Assays | 2 | 2018 | 932 | 0.510 |
Why?
|
| Rats, Wistar | 11 | 2013 | 2020 | 0.500 |
Why?
|
| Data Mining | 1 | 2019 | 543 | 0.500 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2003 | 72 | 0.490 |
Why?
|
| Lupus Nephritis | 1 | 2017 | 328 | 0.490 |
Why?
|
| Gentamicins | 7 | 2012 | 263 | 0.490 |
Why?
|
| Arsenic | 1 | 2016 | 323 | 0.480 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2010 | 172 | 0.450 |
Why?
|
| Rats | 35 | 2021 | 25090 | 0.450 |
Why?
|
| Environmental Pollutants | 4 | 2016 | 1038 | 0.450 |
Why?
|
| Creatinine | 10 | 2016 | 1902 | 0.430 |
Why?
|
| Drug Evaluation, Preclinical | 6 | 2019 | 1408 | 0.430 |
Why?
|
| Protein Biosynthesis | 2 | 2016 | 2168 | 0.430 |
Why?
|
| Animals | 65 | 2021 | 170726 | 0.420 |
Why?
|
| Proteinuria | 8 | 2009 | 623 | 0.400 |
Why?
|
| Kinetochores | 1 | 2011 | 193 | 0.390 |
Why?
|
| Drug Industry | 1 | 2017 | 892 | 0.380 |
Why?
|
| Mice, Inbred BALB C | 6 | 2015 | 6677 | 0.380 |
Why?
|
| Kidney Function Tests | 3 | 2014 | 702 | 0.370 |
Why?
|
| Cadmium | 4 | 2015 | 204 | 0.370 |
Why?
|
| Liver Diseases | 2 | 2017 | 1254 | 0.360 |
Why?
|
| Proteome | 1 | 2019 | 1770 | 0.360 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 445 | 0.350 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 2480 | 0.350 |
Why?
|
| Antiviral Agents | 1 | 2020 | 2794 | 0.340 |
Why?
|
| Gene Expression Profiling | 4 | 2014 | 9521 | 0.340 |
Why?
|
| Cell Cycle | 2 | 2018 | 3020 | 0.330 |
Why?
|
| Membrane Proteins | 8 | 2010 | 8093 | 0.320 |
Why?
|
| Albuminuria | 2 | 2010 | 675 | 0.310 |
Why?
|
| Cystatin C | 4 | 2015 | 246 | 0.310 |
Why?
|
| Genetic Markers | 3 | 2020 | 2690 | 0.310 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2027 | 0.310 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 1921 | 0.300 |
Why?
|
| RNA | 3 | 2015 | 2709 | 0.300 |
Why?
|
| Up-Regulation | 8 | 2017 | 4353 | 0.300 |
Why?
|
| Protein Kinases | 1 | 2013 | 1681 | 0.290 |
Why?
|
| Blood Urea Nitrogen | 4 | 2012 | 198 | 0.280 |
Why?
|
| Disease Models, Animal | 9 | 2019 | 18345 | 0.280 |
Why?
|
| Heterozygote | 1 | 2012 | 2791 | 0.280 |
Why?
|
| Mice | 21 | 2019 | 80995 | 0.280 |
Why?
|
| Ureteral Obstruction | 2 | 2019 | 300 | 0.270 |
Why?
|
| Cells, Cultured | 6 | 2019 | 20101 | 0.260 |
Why?
|
| Ischemia | 2 | 2010 | 1939 | 0.250 |
Why?
|
| Heart Diseases | 1 | 2017 | 2763 | 0.250 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 8016 | 0.240 |
Why?
|
| Oxidative Stress | 5 | 2016 | 3163 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2020 | 8602 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 4595 | 0.230 |
Why?
|
| Male | 57 | 2021 | 351081 | 0.230 |
Why?
|
| Proteomics | 4 | 2023 | 3256 | 0.220 |
Why?
|
| Gene Deletion | 1 | 2010 | 2832 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2021 | 1981 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5482 | 0.220 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2003 | 522 | 0.210 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2019 | 3364 | 0.210 |
Why?
|
| Glomerular Filtration Rate | 6 | 2019 | 2101 | 0.210 |
Why?
|
| Humans | 52 | 2023 | 715124 | 0.210 |
Why?
|
| Urinalysis | 2 | 2016 | 363 | 0.200 |
Why?
|
| In Situ Hybridization | 2 | 2015 | 1988 | 0.190 |
Why?
|
| Folic Acid | 2 | 2017 | 1245 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2010 | 3970 | 0.180 |
Why?
|
| Polymyxins | 1 | 2018 | 24 | 0.180 |
Why?
|
| Wound Healing | 1 | 2010 | 2797 | 0.180 |
Why?
|
| Kidney Cortex | 1 | 2019 | 185 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 1326 | 0.180 |
Why?
|
| Apoptosis | 8 | 2014 | 10112 | 0.180 |
Why?
|
| Mice, Knockout | 5 | 2017 | 15260 | 0.170 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2021 | 270 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2011 | 5155 | 0.170 |
Why?
|
| Cell Shape | 1 | 2019 | 379 | 0.170 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2009 | 560 | 0.170 |
Why?
|
| DNA Replication Timing | 1 | 2017 | 36 | 0.160 |
Why?
|
| Thioacetamide | 2 | 2010 | 18 | 0.160 |
Why?
|
| HEK293 Cells | 2 | 2017 | 4321 | 0.160 |
Why?
|
| Fluoroimmunoassay | 1 | 2016 | 34 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 6 | 2017 | 22936 | 0.160 |
Why?
|
| Interleukin-6 | 4 | 2014 | 3215 | 0.150 |
Why?
|
| Receptor, trkA | 1 | 2017 | 160 | 0.150 |
Why?
|
| Gene Expression | 7 | 2018 | 8010 | 0.150 |
Why?
|
| ROC Curve | 5 | 2010 | 3526 | 0.150 |
Why?
|
| Fluorides | 1 | 2016 | 124 | 0.150 |
Why?
|
| Muscular Diseases | 1 | 2020 | 557 | 0.150 |
Why?
|
| Signal Transduction | 6 | 2017 | 23973 | 0.140 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 3614 | 0.140 |
Why?
|
| Enzyme Induction | 1 | 2016 | 516 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2021 | 11285 | 0.140 |
Why?
|
| Proliferating Cell Nuclear Antigen | 4 | 2003 | 287 | 0.140 |
Why?
|
| Cyclosporine | 2 | 2010 | 825 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2021 | 935 | 0.140 |
Why?
|
| Ancrod | 1 | 2014 | 8 | 0.140 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 301 | 0.140 |
Why?
|
| Epithelial Cells | 2 | 2018 | 3687 | 0.130 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2016 | 350 | 0.130 |
Why?
|
| Injections, Intraperitoneal | 3 | 2010 | 443 | 0.130 |
Why?
|
| Gene Library | 1 | 2017 | 1093 | 0.130 |
Why?
|
| Mexico | 1 | 2016 | 679 | 0.130 |
Why?
|
| Tyrosine | 2 | 2009 | 1508 | 0.130 |
Why?
|
| Smad2 Protein | 1 | 2014 | 170 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2016 | 21790 | 0.130 |
Why?
|
| Alanine Transaminase | 5 | 2021 | 599 | 0.120 |
Why?
|
| Chloroform | 2 | 2003 | 35 | 0.120 |
Why?
|
| Magnetite Nanoparticles | 1 | 2015 | 320 | 0.120 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 14877 | 0.120 |
Why?
|
| Enzymes | 3 | 2003 | 276 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 1022 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2016 | 682 | 0.120 |
Why?
|
| Lipocalins | 5 | 2014 | 175 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 393 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 3994 | 0.120 |
Why?
|
| Liver Regeneration | 3 | 2003 | 222 | 0.120 |
Why?
|
| Kinetics | 2 | 2016 | 6802 | 0.120 |
Why?
|
| Antigens | 2 | 2009 | 1511 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2003 | 2950 | 0.120 |
Why?
|
| Glutathione Transferase | 3 | 2010 | 616 | 0.120 |
Why?
|
| Area Under Curve | 4 | 2011 | 1693 | 0.120 |
Why?
|
| Renin-Angiotensin System | 2 | 2008 | 760 | 0.110 |
Why?
|
| Nephrosis, Lipoid | 1 | 2012 | 51 | 0.110 |
Why?
|
| Caloric Restriction | 2 | 2007 | 351 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2003 | 1231 | 0.110 |
Why?
|
| Liver | 8 | 2021 | 7647 | 0.110 |
Why?
|
| S Phase | 2 | 2003 | 437 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2016 | 23283 | 0.110 |
Why?
|
| Cryopreservation | 1 | 2016 | 630 | 0.110 |
Why?
|
| Immune System | 1 | 2017 | 806 | 0.110 |
Why?
|
| Immunohistochemistry | 11 | 2010 | 11766 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 3 | 2021 | 411 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2014 | 588 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2010 | 1949 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 988 | 0.100 |
Why?
|
| Computational Biology | 2 | 2014 | 3557 | 0.100 |
Why?
|
| Lead | 1 | 2016 | 808 | 0.100 |
Why?
|
| Time Factors | 8 | 2016 | 41081 | 0.100 |
Why?
|
| Cation Transport Proteins | 1 | 2013 | 332 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 1724 | 0.100 |
Why?
|
| Gene Silencing | 1 | 2017 | 1615 | 0.100 |
Why?
|
| DNA Primers | 2 | 2012 | 2999 | 0.100 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 390 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 653 | 0.100 |
Why?
|
| Disease Progression | 4 | 2021 | 13302 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 19499 | 0.100 |
Why?
|
| Acute-Phase Proteins | 4 | 2014 | 273 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2019 | 3016 | 0.090 |
Why?
|
| Tissue Engineering | 1 | 2020 | 1851 | 0.090 |
Why?
|
| Early Diagnosis | 3 | 2010 | 1194 | 0.090 |
Why?
|
| Blotting, Western | 4 | 2012 | 5441 | 0.090 |
Why?
|
| Cadmium Chloride | 1 | 2009 | 11 | 0.090 |
Why?
|
| Rats, Inbred F344 | 4 | 2013 | 883 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2009 | 4933 | 0.090 |
Why?
|
| Chemokine CXCL10 | 1 | 2010 | 313 | 0.090 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2015 | 830 | 0.090 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1788 | 0.090 |
Why?
|
| Histocytochemistry | 1 | 2010 | 758 | 0.090 |
Why?
|
| Heart Failure, Systolic | 1 | 2010 | 128 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2017 | 2313 | 0.090 |
Why?
|
| Creatine Kinase | 2 | 2021 | 712 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 12425 | 0.090 |
Why?
|
| Soybean Proteins | 1 | 2008 | 71 | 0.090 |
Why?
|
| Regeneration | 2 | 2011 | 1543 | 0.090 |
Why?
|
| Receptors, Vasopressin | 1 | 2008 | 119 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2015 | 752 | 0.090 |
Why?
|
| Toxicogenetics | 1 | 2007 | 30 | 0.080 |
Why?
|
| Mercuric Chloride | 2 | 2008 | 19 | 0.080 |
Why?
|
| Longevity | 3 | 2013 | 1041 | 0.080 |
Why?
|
| Aquaporin 2 | 1 | 2008 | 135 | 0.080 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 659 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 2668 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 804 | 0.080 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2007 | 196 | 0.080 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2007 | 60 | 0.080 |
Why?
|
| Interleukin-8 | 1 | 2010 | 698 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2010 | 13732 | 0.080 |
Why?
|
| Demography | 1 | 2012 | 1621 | 0.080 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2008 | 444 | 0.080 |
Why?
|
| Female | 18 | 2019 | 377334 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2019 | 23511 | 0.080 |
Why?
|
| Isoenzymes | 2 | 2009 | 1810 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 1120 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 2567 | 0.070 |
Why?
|
| Troponin I | 2 | 2021 | 634 | 0.070 |
Why?
|
| Valproic Acid | 1 | 2009 | 447 | 0.070 |
Why?
|
| Renal Replacement Therapy | 1 | 2008 | 256 | 0.070 |
Why?
|
| Thymidine | 2 | 2003 | 346 | 0.070 |
Why?
|
| Base Sequence | 3 | 2015 | 13315 | 0.070 |
Why?
|
| Metabolism | 1 | 2007 | 212 | 0.070 |
Why?
|
| Brain Death | 1 | 2009 | 307 | 0.070 |
Why?
|
| Mercury | 1 | 2007 | 238 | 0.070 |
Why?
|
| Endotoxins | 1 | 2008 | 561 | 0.070 |
Why?
|
| Biological Assay | 1 | 2009 | 658 | 0.070 |
Why?
|
| Diuretics | 1 | 2008 | 584 | 0.070 |
Why?
|
| Neoplasms | 1 | 2014 | 20515 | 0.070 |
Why?
|
| Vasoconstrictor Agents | 1 | 2008 | 637 | 0.070 |
Why?
|
| Iron | 1 | 2013 | 1735 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 6290 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 15258 | 0.070 |
Why?
|
| Sodium, Dietary | 1 | 2008 | 413 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2008 | 1848 | 0.060 |
Why?
|
| Multiple Organ Failure | 1 | 2007 | 375 | 0.060 |
Why?
|
| Renin | 1 | 2006 | 615 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2013 | 8738 | 0.060 |
Why?
|
| Propanols | 1 | 2003 | 15 | 0.060 |
Why?
|
| Argininosuccinate Synthase | 1 | 2023 | 16 | 0.060 |
Why?
|
| Cricetulus | 1 | 2005 | 856 | 0.060 |
Why?
|
| Kidney Transplantation | 2 | 2009 | 4139 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2019 | 7836 | 0.060 |
Why?
|
| DNA Damage | 1 | 2013 | 2467 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 317 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 739 | 0.060 |
Why?
|
| Spironolactone | 1 | 2006 | 365 | 0.060 |
Why?
|
| Middle Aged | 12 | 2016 | 214871 | 0.060 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2012 | 1172 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 1742 | 0.060 |
Why?
|
| Survival | 1 | 2003 | 160 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 2148 | 0.060 |
Why?
|
| CHO Cells | 1 | 2005 | 1442 | 0.060 |
Why?
|
| Adult | 9 | 2017 | 212129 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2018 | 10800 | 0.060 |
Why?
|
| Aging | 3 | 2014 | 8368 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2003 | 508 | 0.050 |
Why?
|
| Glutamate Dehydrogenase | 1 | 2021 | 56 | 0.050 |
Why?
|
| Cytokines | 2 | 2010 | 7225 | 0.050 |
Why?
|
| Osteonectin | 1 | 2021 | 33 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2016 | 4046 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 6046 | 0.050 |
Why?
|
| Cricetinae | 1 | 2005 | 2595 | 0.050 |
Why?
|
| Urodynamics | 1 | 2003 | 360 | 0.050 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 858 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2010 | 1573 | 0.050 |
Why?
|
| Carcinogens | 1 | 2003 | 452 | 0.050 |
Why?
|
| Fructose | 1 | 2023 | 296 | 0.050 |
Why?
|
| Aged | 10 | 2015 | 162674 | 0.050 |
Why?
|
| Protein Binding | 1 | 2013 | 9661 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 7213 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 2268 | 0.050 |
Why?
|
| Glutathione | 1 | 2003 | 616 | 0.050 |
Why?
|
| Myosin Light Chains | 1 | 2020 | 129 | 0.050 |
Why?
|
| Growth Substances | 1 | 2002 | 815 | 0.050 |
Why?
|
| Docosahexaenoic Acids | 1 | 2006 | 853 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 13573 | 0.050 |
Why?
|
| Cytosol | 1 | 2003 | 938 | 0.050 |
Why?
|
| Desmosterol | 1 | 2018 | 4 | 0.050 |
Why?
|
| Lanosterol | 1 | 2018 | 4 | 0.050 |
Why?
|
| Dehydrocholesterols | 1 | 2018 | 14 | 0.050 |
Why?
|
| Serpins | 1 | 2021 | 269 | 0.050 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2003 | 398 | 0.050 |
Why?
|
| Polymyxin B | 1 | 2018 | 51 | 0.050 |
Why?
|
| Obesity | 2 | 2014 | 12192 | 0.040 |
Why?
|
| Renal Circulation | 2 | 2010 | 344 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 14237 | 0.040 |
Why?
|
| Cell Line | 1 | 2013 | 16680 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 864 | 0.040 |
Why?
|
| Uteroglobin | 2 | 2008 | 59 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 4688 | 0.040 |
Why?
|
| Interleukin-18 | 2 | 2011 | 250 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2020 | 481 | 0.040 |
Why?
|
| Colchicine | 3 | 2003 | 251 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 2021 | 595 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 18734 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2006 | 1281 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2021 | 664 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 2334 | 0.040 |
Why?
|
| Stem Cells | 1 | 2010 | 3589 | 0.040 |
Why?
|
| DNA | 4 | 2003 | 7159 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2015 | 11746 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2019 | 955 | 0.040 |
Why?
|
| Mitosis | 1 | 2002 | 1255 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 17395 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2012 | 5028 | 0.040 |
Why?
|
| Transfection | 1 | 2005 | 6143 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2020 | 571 | 0.040 |
Why?
|
| Sepsis | 2 | 2008 | 2474 | 0.040 |
Why?
|
| DNA Replication | 1 | 2003 | 1445 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 7045 | 0.040 |
Why?
|
| Cadherins | 1 | 2021 | 917 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2018 | 335 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2021 | 1097 | 0.040 |
Why?
|
| Prognosis | 4 | 2010 | 29168 | 0.040 |
Why?
|
| Microchip Analytical Procedures | 1 | 2015 | 24 | 0.040 |
Why?
|
| Pediatrics | 2 | 2010 | 3553 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2010 | 293 | 0.030 |
Why?
|
| Smad7 Protein | 1 | 2015 | 44 | 0.030 |
Why?
|
| Osteopontin | 2 | 2007 | 352 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2020 | 1248 | 0.030 |
Why?
|
| Kidney Glomerulus | 2 | 2008 | 691 | 0.030 |
Why?
|
| Necrosis | 2 | 2009 | 1650 | 0.030 |
Why?
|
| Child | 3 | 2021 | 74146 | 0.030 |
Why?
|
| Species Specificity | 1 | 2019 | 2620 | 0.030 |
Why?
|
| Young Adult | 3 | 2016 | 56155 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 39804 | 0.030 |
Why?
|
| Body Weight | 3 | 2014 | 4692 | 0.030 |
Why?
|
| Hypertension | 1 | 2014 | 8247 | 0.030 |
Why?
|
| Rats, Inbred SHR | 1 | 2014 | 202 | 0.030 |
Why?
|
| Dogs | 1 | 2019 | 4047 | 0.030 |
Why?
|
| Testicular Diseases | 1 | 2013 | 71 | 0.030 |
Why?
|
| Software | 1 | 2007 | 4350 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 41181 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 4208 | 0.030 |
Why?
|
| Transferrin | 1 | 2013 | 276 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2021 | 11900 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2021 | 51181 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 462 | 0.030 |
Why?
|
| Models, Animal | 2 | 2010 | 2219 | 0.030 |
Why?
|
| Algorithms | 1 | 2012 | 13669 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 39285 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2012 | 9022 | 0.030 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2011 | 129 | 0.030 |
Why?
|
| Cell Division | 3 | 2003 | 4739 | 0.030 |
Why?
|
| Glucose | 1 | 2003 | 4291 | 0.030 |
Why?
|
| Photomicrography | 1 | 2009 | 76 | 0.020 |
Why?
|
| Testis | 1 | 2013 | 811 | 0.020 |
Why?
|
| Renal Dialysis | 2 | 2011 | 1742 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 2 | 2008 | 1996 | 0.020 |
Why?
|
| Clusterin | 1 | 2009 | 70 | 0.020 |
Why?
|
| Potassium Dichromate | 1 | 2008 | 3 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2014 | 8566 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 2008 | 138 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2009 | 152 | 0.020 |
Why?
|
| Arginine Vasopressin | 1 | 2008 | 134 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2015 | 889 | 0.020 |
Why?
|
| Peroxynitrous Acid | 1 | 2008 | 43 | 0.020 |
Why?
|
| Spiro Compounds | 1 | 2008 | 87 | 0.020 |
Why?
|
| Caseins | 1 | 2008 | 126 | 0.020 |
Why?
|
| Hydrochlorothiazide | 1 | 2008 | 109 | 0.020 |
Why?
|
| Galactosamine | 1 | 2007 | 29 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2009 | 379 | 0.020 |
Why?
|
| Age Factors | 3 | 2012 | 18789 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2012 | 1594 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 9584 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 443 | 0.020 |
Why?
|
| Metallothionein | 1 | 2007 | 65 | 0.020 |
Why?
|
| Oliguria | 1 | 2007 | 20 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 316 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2008 | 343 | 0.020 |
Why?
|
| Losartan | 1 | 2008 | 265 | 0.020 |
Why?
|
| Biopsy | 2 | 2009 | 6750 | 0.020 |
Why?
|
| Claudins | 1 | 2007 | 123 | 0.020 |
Why?
|
| APACHE | 1 | 2007 | 271 | 0.020 |
Why?
|
| Acute Disease | 2 | 2008 | 7177 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 517 | 0.020 |
Why?
|
| Acetylglucosamine | 1 | 2007 | 202 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 970 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 6289 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 3022 | 0.020 |
Why?
|
| Nephritis, Interstitial | 1 | 2006 | 143 | 0.020 |
Why?
|
| Arterioles | 1 | 2006 | 259 | 0.020 |
Why?
|
| Morpholines | 1 | 2008 | 571 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 6538 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 4916 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 720 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 276 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2008 | 2449 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 1366 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2006 | 398 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2006 | 666 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 2006 | 2268 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 680 | 0.020 |
Why?
|
| Epinephrine | 1 | 2008 | 811 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 3705 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 614 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 4980 | 0.020 |
Why?
|
| Bromobenzenes | 1 | 2003 | 3 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 2461 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2006 | 801 | 0.020 |
Why?
|
| Liver Glycogen | 1 | 2003 | 37 | 0.020 |
Why?
|
| Chromatography, Gas | 1 | 2003 | 168 | 0.020 |
Why?
|
| L-Iditol 2-Dehydrogenase | 1 | 2003 | 6 | 0.020 |
Why?
|
| Carbon Tetrachloride | 1 | 2003 | 70 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2003 | 186 | 0.010 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 470 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2003 | 12047 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 2004 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2936 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 2008 | 973 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 1785 | 0.010 |
Why?
|
| Cytoprotection | 1 | 2003 | 218 | 0.010 |
Why?
|
| Tritium | 1 | 2003 | 809 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2009 | 2233 | 0.010 |
Why?
|
| Potassium | 1 | 2006 | 1329 | 0.010 |
Why?
|
| Biphenyl Compounds | 1 | 2006 | 901 | 0.010 |
Why?
|
| Aldosterone | 1 | 2006 | 805 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 2678 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2006 | 1590 | 0.010 |
Why?
|
| Tetrazoles | 1 | 2006 | 792 | 0.010 |
Why?
|
| Spleen | 1 | 2007 | 2476 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2003 | 433 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2006 | 884 | 0.010 |
Why?
|
| Metabolomics | 1 | 2009 | 1379 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2008 | 3963 | 0.010 |
Why?
|
| Adolescent | 2 | 2021 | 84999 | 0.010 |
Why?
|
| Leptin | 1 | 2008 | 1581 | 0.010 |
Why?
|
| Antioxidants | 1 | 2008 | 1689 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2021 | 62186 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6531 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 2252 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 58505 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2002 | 726 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 939 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2009 | 6480 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2003 | 1878 | 0.010 |
Why?
|
| Graft Survival | 1 | 2009 | 3761 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 2064 | 0.010 |
Why?
|
| Critical Illness | 1 | 2011 | 2532 | 0.010 |
Why?
|
| Leukocytes | 1 | 2006 | 2102 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 1748 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8912 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2007 | 2452 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 3933 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 2579 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2007 | 10531 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2007 | 4409 | 0.010 |
Why?
|
| Heart | 1 | 2007 | 4326 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2002 | 2121 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2007 | 5133 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13594 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 4476 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 16011 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2003 | 6293 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 9895 | 0.000 |
Why?
|